151 related articles for article (PubMed ID: 38157540)
1. MRI characteristics of H3 G34-mutant diffuse hemispheric gliomas and possible differentiation from IDH-wild-type glioblastomas in adolescents and young adults.
Shao H; Gong J; Su X; Chen N; Li S; Yang X; Zhang S; Huang Z; Hu W; Gong Q; Liu Y; Yue Q
J Neurosurg Pediatr; 2024 Mar; 33(3):236-244. PubMed ID: 38157540
[TBL] [Abstract][Full Text] [Related]
2. Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: A case series and systematic review.
Kurokawa R; Baba A; Kurokawa M; Pinarbasi ES; Makise N; Ota Y; Kim J; Srinivasan A; Moritani T
J Neuroimaging; 2022 Jan; 32(1):17-27. PubMed ID: 34632671
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.
Picart T; Barritault M; Poncet D; Berner LP; Izquierdo C; Tabouret E; Figarella-Branger D; Idbaïh A; Bielle F; Bourg V; Vandenbos FB; Moyal EC; Uro-Coste E; Guyotat J; Honnorat J; Gabut M; Meyronet D; Ducray F
Neurooncol Adv; 2021; 3(1):vdab061. PubMed ID: 34056608
[TBL] [Abstract][Full Text] [Related]
4. Histone H3.3 G34-mutant Diffuse Gliomas in Adults.
Wang L; Shao L; Li H; Yao K; Duan Z; Zhi C; Song S; Cheng Y; Wang F; Wang W; Piao Y; Gui Q; Lu D; Qi X; Teng L
Am J Surg Pathol; 2022 Feb; 46(2):249-257. PubMed ID: 34352809
[TBL] [Abstract][Full Text] [Related]
5. H3 G34-mutant high-grade glioma.
Lim KY; Won JK; Park CK; Kim SK; Choi SH; Kim T; Yun H; Park SH
Brain Tumor Pathol; 2021 Jan; 38(1):4-13. PubMed ID: 32995948
[TBL] [Abstract][Full Text] [Related]
6. High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope?
Hu W; Duan H; Zhong S; Zeng J; Mou Y
J Transl Med; 2022 Feb; 20(1):64. PubMed ID: 35109850
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
9. Utility of arterial spin labeling for objective assessment of intratumoral microvessels in diffuse hemispheric glioma, H3 G34R-mutant: A case report and literature review.
Kitakami K; Beppu T; Sato Y; Kurose A; Ogasawara K
Radiol Case Rep; 2023 Mar; 18(3):856-861. PubMed ID: 36589502
[TBL] [Abstract][Full Text] [Related]
10. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
11. Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas.
Setyawan NH; Choridah L; Nugroho HA; Malueka RG; Dwianingsih EK
Cancer Imaging; 2024 Jan; 24(1):3. PubMed ID: 38167551
[TBL] [Abstract][Full Text] [Related]
12. Midline invasion predicts poor prognosis in diffuse hemispheric glioma, H3 G34-mutant: an individual participant data review.
Kegoya Y; Otani Y; Inoue Y; Mizuta R; Higaki F; Washio K; Koizumi S; Kurozumi K; Ishida J; Fujii K; Yamamoto N; Tanaka Y; Date I
J Neurooncol; 2024 Mar; 167(1):201-210. PubMed ID: 38427132
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
14. MRI Features May Predict Molecular Features of Glioblastoma in
Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
[TBL] [Abstract][Full Text] [Related]
15. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
17. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
18. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
[TBL] [Abstract][Full Text] [Related]
19. Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.
Sim Y; Choi SH; Lee N; Park YW; Ahn SS; Chang JH; Kim SH; Lee SK
Eur J Radiol; 2024 Apr; 173():111384. PubMed ID: 38422610
[TBL] [Abstract][Full Text] [Related]
20. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
